This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Epigenetic Therapies And Technologies: World Market Prospects 2013-2023

Table 4.5 Epigenetic Therapies and Technologies: Market Shares by Country, 2011-2023

Table 4.6 US Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 4.7 Canadian Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 4.8 European Epigenetic Therapies and Technologies Market by Country, 2011

Table 4.9 Selected Epigenetic Companies Headquartered in the EU, 2012

Table 4.10 European Epigenetic Therapies and Technologies Market: Revenue Forecasts by Leading Country, 2011-2023

Table 4.11 German Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 4.12 UK Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 4.13 Japanese Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 4.14 BRIC Nations (Grouped) Epigenetic Therapies and Technologies Market: Revenue Forecast, 2011-2023

Table 5.1 Epigenetic Therapies Submarket: Drug Revenue Shares, 2011-2023

Table 5.2 Vidaza: Revenue, 2004-2011

Table 5.3 Vidaza: Revenue by Region, H1 2011-2012

Table 5.4 Vidaza: Revenue Forecast, 2011-2023

Table 5.5 Vidaza: Drivers and Restraints, 2013-2023

Table 5.6 Dacogen: Revenue and Royalty Revenue, 2006-2011

Table 5.7 Dacogen: Phase III Clinical Trials, 2012

Table 5.8 Dacogen: Drivers and Restraints, 2013-2023

Table 5.9 Dacogen: Revenue Forecast, 2011-2023

Table 5.10 Zolinza: Drivers and Restraints, 2013-2023

Table 5.11 Zolinza: Revenue Forecast, 2011-2023

Table 5.12 Istodax: Revenue, 2010-2011

Table 5.13 CTCL and PTCL Prevalence by Region

Table 5.14 Istodax: Drivers and Restraints, 2013-2023

Table 5.15 Istodax: Revenue Forecast, 2011-2023

Table 5.16 Selected HDAC Inhibitors in Development, 2012

Table 5.17 NCI Sponsored Trials of Belinostat, 2012

Table 5.18 Belinostat: Revenue Forecast, 2014-2023

Table 5.19 Faridak: Revenue Forecast, 2014-2023

Table 5.20 Drug Mechanisms Being Assessed in Clinical Trials for Breast Cancer and Multiple Myeloma, 2012

Table 5.21 Selected Pipeline for Other Epigenetic Enzyme Inhibitors, 2012

Table 5.22 Selected MiRNA Therapy Pipeline, 2012

Table 5.23 CellCentric's Research Institution Affiliations, 2012

Table 5.24 IkerChem Epigenetic Pipeline, 2012

Table 6.1 Pipeline and Marketed Epigenetic Colorectal Cancer Test Comparison, 2012

9 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs